BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

340 related articles for article (PubMed ID: 27064282)

  • 1. Tyrosine kinase inhibitor NVP-BGJ398 functionally improves FGFR3-related dwarfism in mouse model.
    Komla-Ebri D; Dambroise E; Kramer I; Benoist-Lasselin C; Kaci N; Le Gall C; Martin L; Busca P; Barbault F; Graus-Porta D; Munnich A; Kneissel M; Di Rocco F; Biosse-Duplan M; Legeai-Mallet L
    J Clin Invest; 2016 May; 126(5):1871-84. PubMed ID: 27064282
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Meckel's and condylar cartilages anomalies in achondroplasia result in defective development and growth of the mandible.
    Biosse Duplan M; Komla-Ebri D; Heuzé Y; Estibals V; Gaudas E; Kaci N; Benoist-Lasselin C; Zerah M; Kramer I; Kneissel M; Porta DG; Di Rocco F; Legeai-Mallet L
    Hum Mol Genet; 2016 Jul; 25(14):2997-3010. PubMed ID: 27260401
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sustained phosphorylation of mutated FGFR3 is a crucial feature of genetic dwarfism and induces apoptosis in the ATDC5 chondrogenic cell line via PLCgamma-activated STAT1.
    Harada D; Yamanaka Y; Ueda K; Nishimura R; Morishima T; Seino Y; Tanaka H
    Bone; 2007 Aug; 41(2):273-81. PubMed ID: 17561467
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Constitutively-active FGFR3 disrupts primary cilium length and IFT20 trafficking in various chondrocyte models of achondroplasia.
    Martin L; Kaci N; Estibals V; Goudin N; Garfa-Traore M; Benoist-Lasselin C; Dambroise E; Legeai-Mallet L
    Hum Mol Genet; 2018 Jan; 27(1):1-13. PubMed ID: 29040558
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multikinase activity of fibroblast growth factor receptor (FGFR) inhibitors SU5402, PD173074, AZD1480, AZD4547 and BGJ398 compromises the use of small chemicals targeting FGFR catalytic activity for therapy of short-stature syndromes.
    Gudernova I; Vesela I; Balek L; Buchtova M; Dosedelova H; Kunova M; Pivnicka J; Jelinkova I; Roubalova L; Kozubik A; Krejci P
    Hum Mol Genet; 2016 Jan; 25(1):9-23. PubMed ID: 26494904
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mutant FGFR3 associated with SADDAN disease causes cytoskeleton disorganization through PLCγ1/Src-mediated paxillin hyperphosphorylation.
    Montone R; Romanelli MG; Baruzzi A; Ferrarini F; Liboi E; Lievens PM
    Int J Biochem Cell Biol; 2018 Feb; 95():17-26. PubMed ID: 29242050
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Maternal administration of meclozine for the treatment of foramen magnum stenosis in transgenic mice with achondroplasia.
    Matsushita M; Mishima K; Esaki R; Ishiguro N; Ohno K; Kitoh H
    J Neurosurg Pediatr; 2017 Jan; 19(1):91-95. PubMed ID: 27767902
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Suppressing UPR-dependent overactivation of FGFR3 signaling ameliorates SLC26A2-deficient chondrodysplasias.
    Zheng C; Lin X; Xu X; Wang C; Zhou J; Gao B; Fan J; Lu W; Hu Y; Jie Q; Luo Z; Yang L
    EBioMedicine; 2019 Feb; 40():695-709. PubMed ID: 30685387
    [TBL] [Abstract][Full Text] [Related]  

  • 9. C-Type Natriuretic Peptide Analog as Therapy for Achondroplasia.
    Legeai-Mallet L
    Endocr Dev; 2016; 30():98-105. PubMed ID: 26684019
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Constitutive activation of MEK1 in chondrocytes causes Stat1-independent achondroplasia-like dwarfism and rescues the Fgfr3-deficient mouse phenotype.
    Murakami S; Balmes G; McKinney S; Zhang Z; Givol D; de Crombrugghe B
    Genes Dev; 2004 Feb; 18(3):290-305. PubMed ID: 14871928
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FGFR3 mutation causes abnormal membranous ossification in achondroplasia.
    Di Rocco F; Biosse Duplan M; Heuzé Y; Kaci N; Komla-Ebri D; Munnich A; Mugniery E; Benoist-Lasselin C; Legeai-Mallet L
    Hum Mol Genet; 2014 Jun; 23(11):2914-25. PubMed ID: 24419316
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sixteen years and counting: the current understanding of fibroblast growth factor receptor 3 (FGFR3) signaling in skeletal dysplasias.
    Foldynova-Trantirkova S; Wilcox WR; Krejci P
    Hum Mutat; 2012 Jan; 33(1):29-41. PubMed ID: 22045636
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular basis for the treatment of achondroplasia.
    Yamanaka Y; Ueda K; Seino Y; Tanaka H
    Horm Res; 2003; 60 Suppl 3():60-4. PubMed ID: 14671399
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of the therapeutic potential of a CNP analog in a Fgfr3 mouse model recapitulating achondroplasia.
    Lorget F; Kaci N; Peng J; Benoist-Lasselin C; Mugniery E; Oppeneer T; Wendt DJ; Bell SM; Bullens S; Bunting S; Tsuruda LS; O'Neill CA; Di Rocco F; Munnich A; Legeai-Mallet L
    Am J Hum Genet; 2012 Dec; 91(6):1108-14. PubMed ID: 23200862
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Meclozine facilitates proliferation and differentiation of chondrocytes by attenuating abnormally activated FGFR3 signaling in achondroplasia.
    Matsushita M; Kitoh H; Ohkawara B; Mishima K; Kaneko H; Ito M; Masuda A; Ishiguro N; Ohno K
    PLoS One; 2013; 8(12):e81569. PubMed ID: 24324705
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FGFR3 induces degradation of BMP type I receptor to regulate skeletal development.
    Qi H; Jin M; Duan Y; Du X; Zhang Y; Ren F; Wang Y; Tian Q; Wang X; Wang Q; Zhu Y; Xie Y; Liu C; Cao X; Mishina Y; Chen D; Deng CX; Chang Z; Chen L
    Biochim Biophys Acta; 2014 Jul; 1843(7):1237-47. PubMed ID: 24657641
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Knock-in human FGFR3 achondroplasia mutation as a mouse model for human skeletal dysplasia.
    Lee YC; Song IW; Pai YJ; Chen SD; Chen YT
    Sci Rep; 2017 Feb; 7():43220. PubMed ID: 28230213
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel tyrosine kinase inhibitor restores chondrocyte differentiation and promotes bone growth in a gain-of-function Fgfr3 mouse model.
    Jonquoy A; Mugniery E; Benoist-Lasselin C; Kaci N; Le Corre L; Barbault F; Girard AL; Le Merrer Y; Busca P; Schibler L; Munnich A; Legeai-Mallet L
    Hum Mol Genet; 2012 Feb; 21(4):841-51. PubMed ID: 22072392
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FGFR3 promotes synchondrosis closure and fusion of ossification centers through the MAPK pathway.
    Matsushita T; Wilcox WR; Chan YY; Kawanami A; Bükülmez H; Balmes G; Krejci P; Mekikian PB; Otani K; Yamaura I; Warman ML; Givol D; Murakami S
    Hum Mol Genet; 2009 Jan; 18(2):227-40. PubMed ID: 18923003
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HDAC6 deficiency or inhibition blocks FGFR3 accumulation and improves bone growth in a model of achondroplasia.
    Ota S; Zhou ZQ; Romero MP; Yang G; Hurlin PJ
    Hum Mol Genet; 2016 Oct; 25(19):4227-4243. PubMed ID: 27506979
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.